Application | Comment | Organism |
---|---|---|
medicine | potential target for chemotherapy of virus infection and associated diseases, essential for maturation of infectious virions, development of drugs against the protease should be effective against HIV-2 | Human immunodeficiency virus 2 |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
additional information | no inhibition with 1,10-phenanthroline and phenylmethylsulfonylfluoride or EDTA | Human immunodeficiency virus 2 | |
pepstatin A | - |
Human immunodeficiency virus 2 |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
GAG precursor protein of HIV-2 + H2O | Human immunodeficiency virus 2 | - |
? | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Human immunodeficiency virus 2 | - |
human immunodeficiency virus type 2 | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
GAG precursor protein F16 of HIV-1 + H2O | chemically synthesized aspartyl protease enzyme catalyzes specific processing of the recombinant 43-kDa protein | Human immunodeficiency virus 2 | ? | - |
? | |
GAG precursor protein of HIV-2 + H2O | - |
Human immunodeficiency virus 2 | ? | - |
? |